These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 8558205

  • 1. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
    O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF.
    J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205
    [Abstract] [Full Text] [Related]

  • 2. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
    Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR.
    J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
    [Abstract] [Full Text] [Related]

  • 3. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
    Gallo JM, Brennan J, Hamilton TC, Halbherr T, Laub PB, Ozols RF, O'Dwyer PJ.
    Cancer Res; 1995 Oct 15; 55(20):4507-11. PubMed ID: 7553617
    [Abstract] [Full Text] [Related]

  • 4. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan.
    Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G.
    J Natl Cancer Inst; 1997 Dec 03; 89(23):1789-96. PubMed ID: 9392620
    [Abstract] [Full Text] [Related]

  • 5. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.
    Yao K, Godwin AK, Ozols RF, Hamilton TC, O'Dwyer PJ.
    Cancer Res; 1993 Aug 15; 53(16):3662-6. PubMed ID: 8101766
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
    Smith AC, Liao JT, Page JG, Wientjes MG, Grieshaber CK.
    Cancer Res; 1989 Oct 01; 49(19):5385-91. PubMed ID: 2766304
    [Abstract] [Full Text] [Related]

  • 7. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
    Siemann DW, Beyers KL.
    Br J Cancer; 1993 Dec 01; 68(6):1071-9. PubMed ID: 8260357
    [Abstract] [Full Text] [Related]

  • 8. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
    Kramer RA, Greene K, Ahmad S, Vistica DT.
    Cancer Res; 1987 Mar 15; 47(6):1593-7. PubMed ID: 3815359
    [Abstract] [Full Text] [Related]

  • 9. Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.
    Anderson CP, Matthay KK, Perentesis JP, Neglia JP, Bailey HH, Villablanca JG, Groshen S, Hasenauer B, Maris JM, Seeger RC, Reynolds CP.
    Pediatr Blood Cancer; 2015 Oct 15; 62(10):1739-46. PubMed ID: 26153194
    [Abstract] [Full Text] [Related]

  • 10. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
    Soble MJ, Dorr RT.
    Anticancer Res; 1988 Oct 15; 8(1):17-22. PubMed ID: 3358633
    [Abstract] [Full Text] [Related]

  • 11. Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
    Lacreta FP, Brennan JM, Hamilton TC, Ozols RF, O'Dwyer PJ.
    Drug Metab Dispos; 1994 Oct 15; 22(6):835-42. PubMed ID: 7895599
    [Abstract] [Full Text] [Related]

  • 12. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
    Ono K, Shrieve DC.
    J Natl Cancer Inst; 1987 Oct 15; 79(4):811-5. PubMed ID: 3477662
    [Abstract] [Full Text] [Related]

  • 13. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
    Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC.
    Biochem Pharmacol; 1987 Jan 01; 36(1):147-53. PubMed ID: 3801051
    [Abstract] [Full Text] [Related]

  • 14. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP, Reynolds CP.
    Bone Marrow Transplant; 2002 Aug 01; 30(3):135-40. PubMed ID: 12189530
    [Abstract] [Full Text] [Related]

  • 15. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.
    Anderson CP, Seeger RC, Satake N, Monforte-Munoz HL, Keshelava N, Bailey HH, Reynolds CP.
    J Pediatr Hematol Oncol; 2001 Nov 01; 23(8):500-5. PubMed ID: 11878777
    [Abstract] [Full Text] [Related]

  • 16. In vivo modulation of glutathione by buthionine sulfoximine: effect on marrow response to melphalan.
    Russo A, Tochner Z, Phillips T, Carmichael J, DeGraff W, Friedman N, Fisher J, Mitchell JB.
    Int J Radiat Oncol Biol Phys; 1986 Jul 01; 12(7):1187-9. PubMed ID: 3744938
    [Abstract] [Full Text] [Related]

  • 17. Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells.
    Ongaro A, Pellati A, De Mattei M, De Terlizzi F, Rossi CR, Campana LG.
    Anticancer Drugs; 2015 Mar 01; 26(3):284-92. PubMed ID: 25514113
    [Abstract] [Full Text] [Related]

  • 18. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U, Cao S, Minderman H, Toth K, Skenderis BS, Slovak ML, Rustum YM.
    Clin Cancer Res; 1996 Dec 01; 2(12):1961-8. PubMed ID: 9816155
    [Abstract] [Full Text] [Related]

  • 19. L-S,R-buthionine sulfoximine: historical development and clinical issues.
    Bailey HH.
    Chem Biol Interact; 1998 Apr 24; 111-112():239-54. PubMed ID: 9679558
    [Abstract] [Full Text] [Related]

  • 20. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results.
    O'Dwyer PJ, Hamilton TC, Young RC, LaCreta FP, Carp N, Tew KD, Padavic K, Comis RL, Ozols RF.
    J Natl Cancer Inst; 1992 Feb 19; 84(4):264-7. PubMed ID: 1734088
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.